Since its founding in 1994 by Michael H. Slayton, Ph.D., Guided Therapy Systems (GTS) has become a world leader in ultrasound imaging and therapy with technologies sold across the globe by many of the most recognizable and respected names in medical devices. In fact, GTS is the first company in the world to develop and commercialize products that combine both ultrasound imaging and intense therapeutic ultrasound to offer physicians the unprecedented ability to image and treat with the same equipment, thus targeting and evaluating tissue prior, during and after a procedure.
After many years developing ultrasound imaging systems and transducers for large strategic manufactures, GTS began developing new therapeutic ultrasound technologies. The first applications were minimally invasive and included the identification and destruction of non-resectable tumors. GTS would eventually separate into two companies. Going forward, Guided Therapy Systems would focus solely on incubating new commercial opportunities for its intense therapeutic ultrasound platforms, while the newly formed, Ardent Sound, Inc. would commercialize its own line of ultrasound imaging devices. Ardent Sound remains to this day as GTS’s exclusive FDA registered developer and ISO 13485 certified manufacturer.
GTS’s first commercial success came in the form of Ulthera when GTS brought intense therapeutic ultrasound to the forefront of the aesthetic device landscape. As a result, GTS became the first company in the world to develop and commercialize a product that combines both ultrasound imaging and intense therapeutic ultrasound to offer physicians the unprecedented ability to image and treat with the same equipment, thus targeting and evaluating tissue prior, during and after a procedure. In 2009, Ulthera became the first and remains the only energy-based technology with an FDA indication for non-invasive tissue lift. Since then it has been used to treat millions of patients by physicians around the world.
In addition to the aesthetic industry, GTS has expanded its focus to address chronic pain resulting from injuries to ligaments, tendons and muscles through the creation of Actiosund. This next generation ITU technology is the first and only non-invasive ablative device for pain reduction associated with chronic musculoskeletal injuries. The Actisound system received CE mark in 2018 and is currently available in select European markets as well as Australia and New Zealand.
Today GTS has more than 250 patents issued, published, and pending in support of our imaging and Intense Therapeutic Ultrasound (ITU) technologies as we continue to create new ultrasound technologies.